ARVN News and Press, Arvinas Inc. From 11/25/20

NEW HAVEN, Conn., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming virtual investor conferences: ...

Olema Pharmaceuticals intends to raise $170 million in a U.S. IPO of its common stock. The firm is developing treatments for women's cancers, most particularly various breast cancers. It has a collaboration with major pharma firm Novartis and I value its focus on breast cancer tre...

Arvinas (ARVN): Q3 GAAP EPS of -$0.79 misses by $0.11.Revenue of $7.6M (-74.7% Y/Y) beats by $2.38M.Press Release For further details see: Arvinas EPS misses by $0.11, beats on revenue

– First patient dosed in Phase 2 dose expansion cohort of ARV-110 trial – – Dose escalation for Phase 1/2 clinical trials of ARV-110 and ARV-471 continues ; program updates planned for December 2020 &#x...

Olema Pharmaceuticals has filed to raise $100 million in an IPO, although the final figure may differ. The firm is advancing its OP-1250 drug to treat various women's cancers as a monotherapy and in combination with other drugs. OLMA has a collaboration deal with Novartis, which i...

Gainers: Organogenesis Holdings (ORGO) +22%, Anavex Life Sciences (AVXL) +16%, Precigen (PGEN) +12%, Replimune Group (REPL) +11%, Armata Pharmaceuticals (ARMP) +11%.Losers: Vertex Pharmaceuticals (VRTX) -20%, Aphria (APHA) -16%, Cycl...

Arvinas ([[ARVN]] +1.6%) has announced platform updates and disclosed five additional programs from its preclinical pipeline, utilizing its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designe...

NEW HAVEN, Conn., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced platform updates and disclosed five additional programs from its preclinical pipeline...

NEW HAVEN, Conn., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer, will present a ...

NEW HAVEN, Conn., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a firesid...